Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00069901
Status:
COMPLETED
Last Update Posted:
2008-09-22
First Post:
2003-10-02
Brief Title:
Phase II CT-2103Carboplatin in Ovarian Cancer
Sponsor:
CTI BioPharma
Organization:
CTI BioPharma
Study Overview
Official Title:
CT-2103Carboplatin for Patients With Newly Diagnosed Stage III or IV Ovarian or Primary Peritoneal Cancer A Phase 2 Study
Status:
COMPLETED
Status Verified Date:
2008-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of CT-2103 polyLglutamate-paclitaxel in combination with carboplatin for the treatment of patients with Stage III or IV ovarian or primary peritoneal cancer
Detailed Description:
CT-2103 is a pharmaceutical that links paclitaxel the active ingredient in TaxolR to a biodegradable polyglutamate polymer The objective of this trial is to evaluate the toxicity estimate the response rate progression-free survival and overall survival in patients with newly diagnosed stage III or IV ovarian or primary peritoneal carcinoma treated with CT-2103 in combination with carboplatin
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None